SUSAN FREEMAN was diagnosed with plaque psoriasis and treated with OTEZLA

2017 CORPORATE RESPONSIBILITY REPORT

PASSION FOR THE PATIENT

INTRODUCTION

1 Reporting Period Highlights

2 Message from the Chief Executive Officer

4 Celgene at a Glance

6 About Our Company

10 Corporate Responsibility at Celgene

ENVIRONMENT

70 Tracking Progress on Our 2020Environmental Goals

71 Environmental Sustainability

BUSINESS WITH INTEGRITY

82 Governance

85 Stakeholder Engagement

86 Ethics and Business Conduct

89 Public Policy

96 Supply Chain

GLOBAL REPORTING INITIATIVE INDEX

99 General Disclosures

107 Material Aspects

PATIENTS FIRST

16 Research and Development

23 Patient Safety

25 Access to Treatment

34 Global Health

EMPLOYEES AND COMMUNITIES

42 Our Culture

44 Employees

55 Communities

66 Education and Learning Programs

68 Corporate Giving

TABLE OF CONTENTS

1 15 41

69 81 98

JOINED THE ACCESS ACCELERATED INITIATIVE

Access Accelerated is a partnership of 23 biopharmaceutical companies, including Celgene, developing innovative and sustain-able solutions to improve access to treatment and care for noncommunicable diseases (NCDs) such as cancer and heart disease in low- and middle- income countries.

RECEIVED APPROVAL FOR IDHIFA

In 2017, IDHIFA (enasidenib) was granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation as detected by an FDA-approved test. IDHIFA was developed through a collaboration agreement between Celgene and Agios.

RECOGNIZED FOR REINVESTMENT IN RESEARCH AND DEVELOPMENT (R&D)

Celgene reinvested the highest percentage of revenues back into R&D, as noted in the 2016 EU Industrial R&D Investment Scoreboard from the European Commission which evaluates 2,500 multinational companies across all sectors ofthe economy worldwide.

NAMED #1 BIOPHARMA PARTNER FUNDRAISER

Once again, the Leukemia & Lymphoma Society named Celgene as the #1 biopharma partner fundraiser for Light TheNight Walk. During 2016, 1,028 people on 63 Celgene teams walked, with total contributions amounting to $627,626.

ACHIEVED LEED GOLD CERTIFICATION

Celgenes commitment to building a healthy, sustainable future has been recognized withLEED Gold certification for BuildingL a 180,000-square-foot, state-of-the art office building at Celgenes Summit East, NewJersey headquarters location.

ADVANCED TOWARD OUR 2020 ENVIRONMENTAL GOALS

After setting our prospective quantifiable environmental goals in 2016, we have continued to implement various initiatives to reduce our carbon footprint, increase the purchasing of renewable electricity, reduce our water withdrawal and reduce our solid wastegeneration.

INCLUDED ON THE FTSE4GOOD INDEX

In 2017, Celgene was added to the FTSE4Good Index Series, due to our high rating across environmental, social and governance (ESG) measures and proven Corporate Responsibility track record.

ENHANCED CORPORATE RESPONSIBILITY REPORTING

Every year, we work to increase our corpo-rate responsibility transparency. This year, that work included transitioning to the Global Reporting Initiative (GRI) Standards, the newest generation of the most widely used corporate responsibility reporting guidelines. We are now reporting on more GRI indi-cators than ever before, including on how Celgene contributes to the United Nations Sustainable Development Goals (SDGs).

REPORTING PERIOD HIGHLIGHTS

1CELGENE 2017 CORPORATE RESPONSIBILITY REPORTBUSINESS WITH INTEGRITYENVIRONMENTEMPLOYEES AND COMMUNITIESPATIENTS FIRSTINTRODUCTION

Patients are at the heart of every-

thing Celgene does. Improving

their lives is why we exist. We work

tirelessly to deliver truly innovative

and life-changing therapies.

a collaboration with Agios, which is an exceptional example of how Celgene and its collaborators can positively impact the lives of patients with high unmet needs. Our research teams currently work with more than 70 such industry and academic collaborations.

Bringing treatments such as IDHIFA to market is a direct result of Celgenes industry- leading commitment to reinvesting revenue into research and development (R&D), which includes robust clinical trial activities. Our R&D, medical and patient safety teams work together to develop safe, well-planned and effectively managed clinical trials. At the time of this writing, Celgene was sponsoring more than 230clinical trials examining 33unique compounds, with more than 19,000patients actively enrolled.

Celgenes innovative therapies offer hope to patients with significant medical needs. We are therefore focused on how we can make these medicines accessible for the patients who need them. To that end, Celgene is working across stakeholders to address issues of cost, value and access, including reform of outdated insurance designs that force patients to face high deductibles and high co-insurance for their medicines.

Discovering, developing and commercializing breakthrough medicines for patients with serious unmet medical needs is our mission. We are working to change the course of human health through bold pursuits in science.

As a global leader in disease- altering myeloma treatments, for example, we are helping patients in battling this incurable disease. You can also see our progress in leukemia, where IDHIFA (enasidenib) was granted approval from the U.S. Food and Drug Administration (FDA) for the treat-ment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. These patients have been without options for decades. We developed IDHIFA through

MESSAGE FROM THE CHIEF EXECUTIVE OFFICER

In this report, we explore what that really means at Celgene. We also proudly acknowl-edge the vital role our employees play in both fulfilling our mission as well as contrib-uting to the community, detail the ways in which Celgene manages our environmental footprint to support a healthy planet, and demonstrate our commitment to conducting business with integrity.

2 CELGENE 2017 CORPORATE RESPONSIBILITY REPORT BUSINESS WITH INTEGRITYENVIRONMENTEMPLOYEES AND COMMUNITIESPATIENTS FIRSTINTRODUCTION

Delivering innovative medicines for patients is possible only through the hard work of highly dedicated Celgene employees. We are committed to hiring the best people, and to preparing them for today and tomorrow by cultivating every employees full potential and fostering a culture that rewards high perfor-mance and innovation. We are proud to be known as a place where people want to work: Science magazine ranked Celgene as a top employer in their survey of companies with the best reputations as employers.

Celgene does not operate in a vacuum. We are part of society, and embrace our ability to contribute in a variety of ways. Some examples include programs that encourage employee participation in local charitable events, philanthropy and scholarships for deserving students. We value the opportunity to make a meaningful difference for our communities.

At Celgene, we are also working to be a positive force that helps shape a sustainable future. We are committed to continually improving the environment in which we operate, and have established quantifiable 2020 environmental goals for greenhouse gas emissions, renewable electricity, water with-drawal and solid waste. We hold ourselves accountable to these goals and in this report, provide updates on our progress.

As a company that affects so many peoples lives, we are unwavering in our commitment to conduct business with integrity, transpar-ency and accountability. One mechanism we have in place to uphold this commitment is our Sustainability Committee: a senior-level, cross-functional team that oversees Celgenes integrated corporate responsi-bility strategy. It is responsible for decision making on corporate responsibility-related topics and reviewing the progress of environ-mental initiatives, stakeholder engagement, reporting, and other relevant activities. These efforts are paying off. For example, Celgene was recently included on the FTSE4Good Index due to our high rating across environ-mental, social and governance measures and proven track record of responsibility.

Hard work and dedication to our mission places Celgene in a strong position to achieve consistent and sustainable growth well into the future. Our patients, our partners in health care, our employees and our share-holders expect and deserve that growth. We have the ability not only to achieve our business and strategic objectives, but also to fulfill our responsibilities to society by applying patient focus, forwardlooking practices, strong values, ethics and integrity to every aspect of our work.

MARKJ. ALLESChief Executive Officer

3CELGENE 2017 CORPORATE RESPONSIBILITY REPORTBUSINESS WITH INTEGRITYENVIRONMENTEMPLOYEES AND COMMUNITIESPATIENTS FIRSTINTRODUCTION

~7,000employees globally

$11.2Bin revenue in 2016

231clinical trials currently being sponsored byCelgene

1986Founded in 1986 and headquartered in Summit, New Jersey

39.8%In 2016, Celgene reinvested 39.8% of revenue back into research and development*

33unique compounds being examined in clinical trials

70+Serving patients in 70+ countries

19K+patients actively enrolled in clinical trials

22pivotal/PhaseIII programs currently underway

Celge